About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Fas
Fas cell surface death receptor
MGI:95484
218 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Agtpbp1atms/Agtpbp1atms
Faslpr/?
MRL/Mp-Agtpbp1atms Faslpr 		abnormal cerebellar foliation J:103945
abnormal cerebellum morphology J:103945
abnormal stellate ganglion morphology J:103945
arrest of spermatogenesis J:103945
ataxia J:103945
decreased brain weight J:103945
decreased Purkinje cell number J:103945
female infertility J:103945
impaired coordination J:103945
male infertility J:103945
oligozoospermia J:103945
small cerebellum J:103945
thin cerebellar granule layer J:103945
thin cerebellar molecular layer J:103945
Agtpbp1atms/Agtpbp1atms
Faslpr/Faslpr
MRL/Mp-Agtpbp1atms Faslpr 		ataxia J:103944
enlarged lymph nodes J:103944
enlarged spleen J:103944
normal integument phenotype J:103944
Apoetm1Unc/Apoetm1Unc
Faslpr/Faslpr
B6.Cg-Apoetm1Unc Faslpr 		abnormal aorta morphology J:121671
abnormal heart morphology J:121671
abnormal trabecular bone morphology J:121671
abnormal vascular endothelial cell morphology J:121671
atherosclerotic lesions J:121671
decreased autoantibody level J:121671
decreased bone mineral density J:121671
decreased bone mineral density of femur J:121671
decreased bone mineral density of vertebrae J:121671
decreased bone trabecula number J:121671
decreased CD4-positive, alpha-beta T cell number J:121671
decreased CD8-positive, alpha-beta T cell number J:121671
decreased circulating cholesterol level J:121671
decreased trabecular bone connectivity density J:121671
decreased trabecular bone thickness J:121671
decreased trabecular bone volume J:121671
enlarged lymph nodes J:121671
enlarged spleen J:121671
enlarged thymus J:121671
glomerulonephritis J:121671
normal hematopoietic system phenotype J:121671
increased anti-double stranded DNA antibody level J:121671
increased autoantibody level J:121671
increased IgG level J:121671
increased kidney apoptosis J:121671
increased renal glomerulus lobularity J:121671
increased renal tubule apoptosis J:121671
increased urine protein level J:121671
renal glomerular immunoglobulin deposits J:121671
renal glomerulus hypertrophy J:121671
Apoetm1Unc/Apoetm1Unc
Faslpr/Faslpr
MRL.Cg-Apoetm1Unc Faslpr 		increased anti-double stranded DNA antibody level J:133606
increased anti-nuclear antigen antibody level J:133606
increased autoantibody level J:133606
increased circulating cholesterol level J:133606
increased immunoglobulin level J:133606
increased susceptibility to atherosclerosis J:133606
increased susceptibility to systemic lupus erythematosus J:133606
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
Faslpr/Faslpr
B6.Cg-Bcl2l11tm1.1Ast Faslpr 		abnormal effector T cell morphology J:132217
abnormal glomerular capillary morphology J:132217
abnormal kidney morphology J:132217
abnormal lymph node cell ratio J:132217
abnormal renal glomerulus basement membrane morphology J:132217
abnormal renal glomerulus morphology J:132217
abnormal splenic cell ratio J:132217
abnormal T cell number J:132217
abnormal T cell subpopulation ratio J:132217
decreased B cell number J:132217
decreased spleen red pulp amount J:132217
enlarged lymph nodes J:132217
enlarged spleen J:132217
expanded mesangial matrix J:132217
increased anti-double stranded DNA antibody level J:132217
increased anti-histone antibody level J:132217
increased anti-nuclear antigen antibody level J:132217
increased anti-single stranded DNA antibody level J:132217
increased autoantibody level J:132217
increased dendritic cell number J:132217
increased follicular B cell number J:132217
increased immature B cell number J:132217
increased kidney cell proliferation J:132217
increased leukocyte cell number J:132217
increased macrophage cell number J:132217
increased marginal zone B cell number J:132217
increased memory T cell number J:132217
increased renal glomerulus apoptosis J:132217
increased renal glomerulus basement membrane thickness J:132217
increased spleen white pulp amount J:132217
increased susceptibility to autoimmune disorder J:132217
increased transitional stage B cell number J:132217
lymph node hyperplasia J:132217
renal glomerulus hypertrophy J:132217
spleen hyperplasia J:132217
C3tm1Crr/C3tm1Crr
C4btm1Crr/C4btm1Crr
Faslpr/Faslpr
involves: 129S4/SvJae * C57BL/6 * MRL 		abnormal immune system physiology J:127292
abnormal kidney morphology J:127292
abnormal renal glomerulus morphology J:127292
enlarged cervical lymph nodes J:127292
enlarged spleen J:127292
increased anti-double stranded DNA antibody level J:127292
increased anti-nuclear antigen antibody level J:127292
C3tm1Crr/C3tm1Crr
Faslpr/Faslpr
involves: 129S4/SvJae * C57BL/6 * MRL 		abnormal renal glomerulus morphology J:127292
decreased susceptibility to autoimmune disorder J:127292
normal immune system phenotype J:127292
C4btm1Crr/C4btm1Crr
Faslpr/Faslpr
involves: 129S4/SvJae * C57BL/6 * MRL 		abnormal immune system physiology J:127292
abnormal kidney morphology J:127292
abnormal renal glomerulus morphology J:127292
enlarged cervical lymph nodes J:127292
enlarged spleen J:127292
increased anti-double stranded DNA antibody level J:127292
increased anti-nuclear antigen antibody level J:127292
Ccr2tm1Blck/Ccr2tm1Blck
Faslpr/Faslpr
MRL.Cg-Ccr2tm1Blck Faslpr 		abnormal immune system organ morphology J:113343
abnormal interferon level J:113343
abnormal lymphocyte cell number J:113343
abnormal renal glomerulus morphology J:113343
abnormal tumor necrosis factor level J:113343
albuminuria J:113343
enlarged lymph nodes J:113343
enlarged spleen J:113343
expanded mesangial matrix J:113343
glomerulonephritis J:113343
glomerulosclerosis J:113343
kidney inflammation J:113343
premature death J:113343
renal tubule atrophy J:113343
Cd40lgtm1Flv/Cd40lgtm1Flv
Faslpr/Faslpr
involves: 129P2/OlaHsd * 129S2/SvPas * MRL 		abnormal kidney morphology J:38492
alopecia J:38492
decreased autoantibody level J:38492
decreased IgG level J:38492
decreased immunoglobulin level J:38492
extended life span J:38492
skin lesions J:38492
Cd40lgtm1Flv/Cd40lgtm1Flv
Faslpr/Faslpr
Tcratm1Mjo/Tcratm1Mjo
involves: 129P2/OlaHsd * 129S2/SvPas * MRL 		abnormal kidney morphology J:38492
decreased autoantibody level J:38492
increased anti-double stranded DNA antibody level J:38492
normal integument phenotype J:38492
Cd40lgtm1Flv/Y
Faslpr/Faslpr
involves: 129P2/OlaHsd * 129S2/SvPas * MRL 		abnormal kidney morphology J:38492
alopecia J:38492
decreased autoantibody level J:38492
decreased IgG level J:38492
decreased immunoglobulin level J:38492
extended life span J:38492
skin lesions J:38492
Cd40lgtm1Flv/Y
Faslpr/Faslpr
Tcratm1Mjo/Tcratm1Mjo
involves: 129P2/OlaHsd * 129S2/SvPas * MRL 		abnormal kidney morphology J:38492
decreased autoantibody level J:38492
increased anti-double stranded DNA antibody level J:38492
normal integument phenotype J:38492
Cd72b/Cd72b
Faslpr/Faslpr
involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp 		abnormal B cell number J:204782
abnormal renal glomerulus morphology J:204782
abnormal T cell number J:204782
abnormal urine protein level J:204782
autoimmune response J:204782
decreased anti-double stranded DNA antibody level J:204782
decreased anti-nuclear antigen antibody level J:204782
decreased IgG level J:204782
decreased spleen weight J:204782
decreased susceptibility to autoimmune disorder J:204782
renal glomerular protein deposits J:204782
Cd72c/Cd72c
Faslpr/Faslpr
involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp 		abnormal B cell number J:204782
abnormal T cell number J:204782
autoimmune response J:204782
cortical renal glomerulopathies J:204782
enlarged lymph nodes J:204782
increased anti-chromatin antibody level J:204782
increased anti-double stranded DNA antibody level J:204782
increased anti-single stranded DNA antibody level J:204782
increased IgG level J:204782
increased spleen weight J:204782
increased susceptibility to systemic lupus erythematosus J:204782
liver inflammation J:204782
lung inflammation J:204782
Cd72tm1Tsub/Cd72tm1Tsub
Faslpr/Faslpr
involves: C57BL/6J * C57BL/6JJmsSlc * MRL/Mp 		abnormal B cell number J:204782
abnormal T cell number J:204782
autoimmune response J:204782
enlarged lymph nodes J:204782
glomerulonephritis J:204782
increased anti-chromatin antibody level J:204782
increased anti-double stranded DNA antibody level J:204782
increased anti-single stranded DNA antibody level J:204782
increased spleen weight J:204782
liver inflammation J:204782
lung inflammation J:204782
renal glomerular immunoglobulin deposits J:204782
Cd180tm1Kmiy/Cd180tm1Kmiy
Faslpr/Faslpr
MRL.Cg-Cd180tm1Kmiy Faslpr 		abnormal blood urea nitrogen level J:137066
blood vessel inflammation J:137066
decreased B cell number J:137066
decreased CD8-positive, alpha-beta T cell number J:137066
decreased IgG2a level J:137066
decreased IgG3 level J:137066
enlarged lymph nodes J:137066
enlarged spleen J:137066
glomerulonephritis J:137066
normal hematopoietic system phenotype J:137066
increased anti-nuclear antigen antibody level J:137066
increased autoantibody level J:137066
increased double-negative T cell number J:137066
normal mortality/aging J:137066
Dntttm1Gfn/Dntttm1Gfn
Faslpr/Faslpr
involves: 129S2/SvPas * C57BL/6 * MRL/MpJ 		decreased autoantibody level J:110248
Dsg4hage/Dsg4hage
Faslpr/Faslpr
X/Yaa
EOD-Dsg4hage 		abnormal effector T cell morphology J:140028
abnormal hair follicle morphology J:140028
abnormal hair follicle orientation J:140028
abnormal mast cell morphology J:140028
absent vibrissae J:140028
decreased body size J:140028
extended life span J:140028
sparse hair J:140028
thick epidermis J:140028
Ebi3tm1Nkma/Ebi3tm1Nkma
Faslpr/Faslpr
MRL.Cg-Ebi3tm1Nkma Faslpr 		abnormal blood homeostasis J:181669
abnormal cytokine level J:181669
abnormal glomerular capillary morphology J:181669
abnormal kidney physiology J:181669
abnormal renal protein reabsorption J:181669
decreased blood urea nitrogen level J:181669
decreased circulating creatine level J:181669
decreased circulating creatinine level J:181669
decreased circulating interferon-gamma level J:181669
increased circulating interleukin-4 level J:181669
increased IgE level J:181669
increased IgG1 level J:181669
increased IgG level J:181669
increased immunoglobulin level J:181669
increased urine protein level J:181669
premature death J:181669
Faslpr/Fas+
Raf1tm1Bacc/Raf1+
involves: 129/SvHsd * 129P2/OlaHsd * C57BL/6 * MRL 		normal hematopoietic system phenotype J:135681
Faslpr/Fas+
Raf1tm1Bacc/Raf1tm1Bacc
involves: 129/SvHsd * 129P2/OlaHsd * C57BL/6 * MRL 		abnormal erythropoiesis J:135681
normal hematopoietic system phenotype J:135681
normal mortality/aging J:135681
Faslpr/Fas+
Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6 * MRL/Mp 		liver inflammation J:72817
normal liver/biliary system phenotype J:72817
normal mortality/aging J:72817
Faslpr/Faslpr
Fasltm2.1Bksa/Fasltm2.1Bksa
involves: 129 * C57BL/6 * MRL/Mp 		abnormal retina ganglion cell morphology J:171440
normal vision/eye phenotype J:171440
Faslpr/Faslpr
Fcer1gtm1Tks/Fcer1gtm1Tks
MRL.Cg-Fcer1gtm1Tks Faslpr 		abnormal glomerular capillary endothelium morphology J:106188
arteritis J:106188
decreased susceptibility to type III hypersensitivity reaction J:106188
glomerular crescent J:106188
glomerulonephritis J:106188
normal immune system phenotype J:106188
increased anti-double stranded DNA antibody level J:106188
increased double-negative T cell number J:106188
increased IgG level J:106188
increased kidney cell proliferation J:106188
increased mesangial cell number J:106188
increased spleen weight J:106188
increased urine protein level J:106188
kidney failure J:106188
premature death J:106188
vascular inflammation J:106188
Faslpr/Faslpr
Havcr1tm1Kuch/Havcr1tm1Kuch
B6.Cg-Havcr1tm1Kuch Faslpr 		abnormal immunoglobulin level J:186484
enlarged lymph nodes J:186484
enlarged spleen J:186484
increased activated T cell number J:186484
increased anti-double stranded DNA antibody level J:186484
increased autoantibody level J:186484
increased B cell number J:186484
increased CD4-positive, alpha-beta T cell number J:186484
increased CD8-positive, alpha-beta T cell number J:186484
increased double-negative T cell number J:186484
increased IgG1 level J:186484
increased IgG2a level J:186484
increased IgG2b level J:186484
increased IgG3 level J:186484
increased susceptibility to systemic lupus erythematosus J:186484
increased T cell number J:186484
Faslpr/Faslpr
Hspa13tm1.1Smoc/Hspa13tm1.1Smoc
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp 		decreased autoantibody level J:303927
decreased susceptibility to systemic lupus erythematosus J:303927
increased urine protein level J:303927
Faslpr/Faslpr
Ifnar1tm1Agt/Ifnar1tm1Agt
MRL.Cg-Ifnar1tm1Agt Faslpr 		enlarged lymph nodes J:92084
glomerulonephritis J:92084
increased anti-nuclear antigen antibody level J:92084
increased autoantibody level J:92084
increased IgA level J:92084
increased IgG2b level J:92084
increased IgG3 level J:92084
increased IgG level J:92084
increased IgM level J:92084
increased susceptibility to systemic lupus erythematosus J:92084
increased urine protein level J:92084
salivary gland inflammation J:92084
Faslpr/Faslpr
Ifnar1tm1Agt/Ifnar1tm1Agt
Ifngr1tm1Agt/Ifngr1tm1Agt
MRL.Cg-Ifngr1tm1Agt Ifnar1tm1Agt Faslpr 		decreased anti-nuclear antigen antibody level J:92084
decreased autoantibody level J:92084
decreased IgG level J:92084
decreased susceptibility to systemic lupus erythematosus J:92084
glomerulonephritis J:92084
increased IgG level J:92084
increased susceptibility to systemic lupus erythematosus J:92084
increased urine protein level J:92084
salivary gland inflammation J:92084
small lymph nodes J:92084
Faslpr/Faslpr
Ifngtm1Ts/Ifng+
MRL.Cg-Ifngtm1Ts Faslpr 		abnormal glomerular capillary morphology J:123834
abnormal macrophage chemotaxis J:123834
abnormal renal glomerulus morphology J:123834
glomerulonephritis J:123834
increased autoantibody level J:123834
increased blood urea nitrogen level J:123834
increased mesangial cell number J:123834
premature death J:123834
Faslpr/Faslpr
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp 		abnormal lymph node size J:39600
abnormal spleen size J:39600
decreased anti-double stranded DNA antibody level J:39600
decreased anti-nuclear antigen antibody level J:39600
decreased autoantibody level J:39600
decreased circulating creatinine level J:39600
decreased double-negative T cell number J:39600
decreased IgA level J:39600
decreased IgG2a level J:39600
decreased IgG2b level J:39600
decreased IgM level J:39600
decreased immunoglobulin level J:39600
decreased susceptibility to systemic lupus erythematosus J:39600
enlarged lymph nodes J:39600
enlarged spleen J:39600
Faslpr/Faslpr
Ifngtm1Ts/Ifngtm1Ts
MRL.Cg-Ifngtm1Ts Faslpr 		abnormal macrophage chemotaxis J:123834
abnormal renal glomerulus morphology J:123834
normal immune system phenotype J:123834
kidney inflammation J:123834
lung inflammation J:123834
Faslpr/Faslpr
Ifngr1tm1Agt/Ifngr1tm1Agt
MRL.Cg-Ifngr1tm1Agt Faslpr 		decreased anti-nuclear antigen antibody level J:92084
decreased autoantibody level J:92084
decreased IgA level J:92084
decreased IgG2a level J:92084
decreased IgG2b level J:92084
decreased IgG3 level J:92084
decreased IgM level J:92084
decreased susceptibility to systemic lupus erythematosus J:92084
glomerulonephritis J:92084
increased IgG1 level J:92084
increased IgG level J:92084
increased urine protein level J:92084
small lymph nodes J:92084
Faslpr/Faslpr
Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
MRL.Cg-Faslpr Igh-Jtm2(3H9-VDJ*)Mwg 		abnormal B cell receptor editing J:131138
abnormal marginal zone B cell morphology J:131138
increased anti-double stranded DNA antibody level J:131138
Faslpr/Faslpr
Ighmtm1Cgn/Ighmtm1Cgn
involves: 129S2/SvPas * C57BL/6 * MRL/Mp 		abnormal humoral immune response J:119584
abnormal immunoglobulin level J:119584
arrested B cell differentiation J:119584
decreased IgM level J:119584
decreased mature B cell number J:119584
enlarged lymph nodes J:119584
increased autoantibody level J:119584
increased T cell number J:119584
increased urine protein level J:119584
Faslpr/Faslpr
Il2ratm1Dw/Il2ratm1Dw
Tg(CD2-Ccdc86)1Hfuj/?
B6.Cg-Il2ratm1Dw Faslpr Tg(CD2-Ccdc86)1Hfuj 		enlarged spleen J:151722
Faslpr/Faslpr
Il4tm1Cgn/Il4tm1Cgn
involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp 		abnormal lymph node size J:39600
abnormal spleen size J:39600
decreased anti-nuclear antigen antibody level J:39600
decreased circulating creatinine level J:39600
decreased IgA level J:39600
decreased IgE level J:39600
decreased IgG1 level J:39600
decreased IgG3 level J:39600
decreased immunoglobulin level J:39600
decreased susceptibility to systemic lupus erythematosus J:39600
enlarged spleen J:39600
increased spleen weight J:39600
spleen hyperplasia J:39600
Faslpr/Faslpr
Il4tm1Cgn/Il4tm1Cgn
MRL.Cg-Il4tm1Cgn Faslpr 		glomerulonephritis J:132514
lacrimal gland inflammation J:132514
Faslpr/Faslpr
Il27ratm1Mak/Il27ratm1Mak
MRL.Cg-Il27ratm1Mak Faslpr 		abnormal T-helper 2 physiology J:122148
decreased anti-double stranded DNA antibody level J:122148
decreased blood urea nitrogen level J:122148
decreased circulating creatinine level J:122148
decreased IgG2a level J:122148
decreased interferon-gamma secretion J:122148
decreased susceptibility to systemic lupus erythematosus J:122148
extended life span J:122148
glomerulonephritis J:122148
normal immune system phenotype J:122148
increased circulating interleukin-4 level J:122148
increased circulating interleukin-5 level J:122148
increased IgE level J:122148
increased IgG1 level J:122148
Faslpr/Faslpr
Irf1tm1Mak/Irf1+
MRL.Cg-Irf1tm1Mak Faslpr 		abnormal skin condition J:114771
glomerulonephritis J:114771
normal immune system phenotype J:114771
increased anti-double stranded DNA antibody level J:114771
increased CD4-positive, alpha-beta T cell number J:114771
increased urine protein level J:114771
premature death J:114771
Faslpr/Faslpr
Irf1tm1Mak/Irf1tm1Mak
MRL.Cg-Irf1tm1Mak Faslpr 		abnormal cell physiology J:114771
abnormal cytokine secretion J:114771
decreased anti-double stranded DNA antibody level J:114771
glomerulonephritis J:114771
normal homeostasis/metabolism phenotype J:114771
normal immune system phenotype J:114771
increased CD4-positive, alpha-beta T cell number J:114771
normal integument phenotype J:114771
premature death J:114771
Faslpr/Faslpr
Itfg2Gt(OST215121)Lex/Itfg2Gt(OST215121)Lex
involves: 129S5/SvEvBrd * C57BL/6J * MRL/Mp 		decreased B cell number J:205951
enlarged lymph nodes J:205951
enlarged spleen J:205951
increased anti-double stranded DNA antibody level J:205951
increased anti-nuclear antigen antibody level J:205951
increased double-negative T cell number J:205951
increased IgG2a level J:205951
increased IgM level J:205951
increased susceptibility to systemic lupus erythematosus J:205951
increased urine protein level J:205951
Faslpr/Faslpr
Kdelr1m1Btlr/Kdelr1m1Btlr
involves: C57BL/6J * MRL/Mp 		normal immune system phenotype J:224970
Faslpr/Faslpr
Nos2tm1Mrl/Nos2tm1Mrl
involves: 129S7/SvEvBrd * MRL 		abnormal blood homeostasis J:42666
abnormal immunoglobulin level J:42666
abnormal urine homeostasis J:42666
decreased IgG level J:42666
decreased IgM level J:42666
decreased urine nitrite level J:42666
normal immune system phenotype J:42666
Faslpr/Faslpr
Pou2af1tm1Pmt/Pou2af1tm1Pmt
involves: 129P2/OlaHsd * C57BL/6 * MRL 		abnormal renal glomerulus morphology J:125114
abnormal T cell number J:125114
autoimmune response J:125114
decreased immunoglobulin level J:125114
decreased plasma cell number J:125114
glomerular crescent J:125114
normal hematopoietic system phenotype J:125114
increased B cell number J:125114
normal mortality/aging J:125114
renal glomerulus hypertrophy J:125114
Faslpr/Faslpr
Raf1tm1Bacc/Raf1tm1Bacc
involves: 129/SvHsd * 129P2/OlaHsd * C57BL/6 * MRL 		abnormal erythropoiesis J:135681
increased apoptosis J:135681
Faslpr/Faslpr
Selptm1Bay/Selptm1Bay
MRL.Cg-Selptm1Bay Faslpr 		abnormal chemokine secretion J:127199
abnormal glomerular capillary endothelium morphology J:127199
abnormal leukocyte adhesion J:126009
abnormal renal glomerular capsule morphology J:127199
abnormal renal glomerulus morphology J:127199
dermatitis J:127199
expanded mesangial matrix J:127199
fused podocyte foot processes J:127199
glomerular crescent J:127199
glomerulonephritis J:127199
impaired leukocyte tethering or rolling J:126009
increased mesangial cell number J:127199
increased neutrophil cell number J:127199
kidney failure J:127199
podocyte foot process effacement J:127199
premature death J:127199
renal glomerular synechia J:127199
renal glomerulus fibrosis J:127199
renal necrosis J:127199
renal tubule atrophy J:127199
vascular inflammation J:127199
Faslpr/Faslpr
Selplgtm1Fur/Selplgtm1Fur
MRL.Cg-Selplgtm1Fur Faslpr 		abnormal chemokine level J:127199
dermatitis J:127199
glomerulonephritis J:127199
premature death J:127199
Faslpr/Faslpr
Sh2d1arpl/Sh2d1arpl
MRL/Mp-Faslpr Sh2d1arpl 		abnormal immune system physiology J:126261
increased anti-nuclear antigen antibody level J:126261
Faslpr/Faslpr
Spp1tm1Rit/Spp1tm1Rit
involves: 129S7/SvEvBrd * C57BL/6 * MRL/Mp 		enlarged spleen J:73396
increased anti-double stranded DNA antibody level J:73396
increased anti-single stranded DNA antibody level J:73396
increased IgA level J:73396
increased IgG1 level J:73396
increased IgG2a level J:73396
increased IgG2b level J:73396
increased IgG3 level J:73396
increased IgM level J:73396
kidney inflammation J:73396
lymph node hyperplasia J:73396
Faslpr/Faslpr
Tcratm1Mjo/Tcra+
MRL.Cg-Tcratm1Mjo Faslpr 		normal immune system phenotype J:108590
Faslpr/Faslpr
Tcratm1Mjo/Tcratm1Mjo
involves: 129P2/OlaHsd * 129S2/SvPas * MRL 		abnormal kidney morphology J:38492
decreased autoantibody level J:38492
decreased immunoglobulin level J:38492
extended life span J:38492
skin lesions J:38492
Faslpr/Faslpr
Tcratm1Mjo/Tcratm1Mjo
involves: 129P2/OlaHsd * MRL 		abnormal kidney morphology J:45448
abnormal renal glomerulus morphology J:45448
normal immune system phenotype J:26250
increased blood urea nitrogen level J:45448
increased gamma-delta intraepithelial T cell number J:26250
increased gamma-delta T cell number J:26250
increased T cell number J:26250
increased urine protein level J:45448
kidney inflammation J:45448
Faslpr/Faslpr
Tg(CD2-Foxj1)#Stlp/0
MRL.Cg-Faslpr Tg(CD2-Foxj1)#Stlp 		abnormal T cell physiology J:122222
decreased CD4-positive, alpha-beta T cell number J:122222
decreased susceptibility to systemic lupus erythematosus J:122222
enlarged lymph nodes J:122222
enlarged spleen J:122222
increased anti-nuclear antigen antibody level J:122222
increased double-negative T cell number J:122222
kidney inflammation J:122222
liver inflammation J:122222
lung inflammation J:122222
salivary gland inflammation J:122222
Faslpr/Faslpr
Tg(H2-K-Cd86)27All/0
involves: C57BL/6 * CBA * MRL/MpJ 		decreased B cell number J:112475
Faslpr/Faslpr
Tg(Ins2-Fasl)24Ach/0
NOD.Cg-Faslpr Tg(Ins2-Fasl)24Ach 		decreased susceptibility to autoimmune diabetes J:81416
Faslpr/Faslpr
Tg(INS-Il10)#Sar/0
NOD.Cg-Faslpr Tg(INS-Il10)#Sar 		increased susceptibility to autoimmune diabetes J:64051
insulitis J:64051
Faslpr/Faslpr
Tlr7tm1Flv/Y
involves: 129S1/Sv * C57BL/6 * MRL/Mp 		abnormal B cell activation J:113557
abnormal CD4-positive, alpha beta T cell morphology J:113557
abnormal lymph node size J:113557
abnormal plasmacytoid dendritic cell physiology J:113557
decreased autoantibody level J:113557
decreased double-negative T cell number J:113557
decreased IgG2a level J:113557
decreased IgG3 level J:113557
decreased spleen weight J:113557
decreased susceptibility to systemic lupus erythematosus J:113557
increased anti-chromatin antibody level J:113557
increased autoantibody level J:113557
Faslpr/Faslpr
Tlr9tm1Aki/Tlr9tm1Aki
B6.Cg-Tlr9tm1Aki Faslpr 		autoimmune response J:135036
decreased IgM level J:135036
enlarged lymph nodes J:135036
enlarged spleen J:135036
glomerulonephritis J:135036
increased double-negative T cell number J:135036
increased IgG level J:135036
increased urine protein level J:135036
premature death J:135036
renal glomerular immunoglobulin deposits J:135036
Faslpr/Faslpr
Tlr9tm1Aki/Tlr9tm1Aki
MRL.Cg-Tlr9tm1Aki Faslpr 		abnormal B cell activation J:113557
abnormal plasmacytoid dendritic cell physiology J:113557
abnormal renal glomerulus morphology J:113557
decreased autoantibody level J:113557
enlarged lymph nodes J:113557
enlarged spleen J:113557
glomerulonephritis J:113557
increased autoantibody level J:113557
increased CD4-positive, alpha-beta T cell number J:113557
increased circulating interferon-alpha level J:113557
increased double-negative T cell number J:113557
increased IgG2a level J:113557
increased IgG3 level J:113557
increased IgG level J:113557
increased susceptibility to systemic lupus erythematosus J:113557
kidney inflammation J:113557
premature death J:113557
Faslpr/Faslpr
Tnfrsf1atm1.1Gkl/Tnfrsf1atm1.1Gkl
involves: 129/Sv * C57BL/6 		liver inflammation J:92470
Faslpr/Faslpr
Tnfrsf9tm1Byk/Tnfrsf9tm1Byk
MRL.Cg-Tnfrsf9tm1Byk Faslpr 		abnormal kidney morphology J:126929
abnormal lacrimal gland morphology J:126929
abnormal outer ear morphology J:127197
cortical renal glomerulopathies J:127197
enlarged lymph nodes J:127197
enlarged spleen J:127197
normal hematopoietic system phenotype J:127197
increased anti-nuclear antigen antibody level J:127197
increased B-1 B cell number J:127197
increased B-2 B cell number J:127197
increased CD4-positive, alpha-beta T cell number J:126929, J:127197
increased double-negative T cell number J:126929, J:127197
increased immunoglobulin level J:127197
increased interleukin-4 secretion J:126929
increased lacrimal gland apoptosis J:126929
increased spleen germinal center number J:127197
increased susceptibility to systemic lupus erythematosus J:127197
lacrimal gland inflammation J:126929
premature death J:127197
renal glomerular protein deposits J:127197
skin lesions J:127197
Faslpr/Faslpr
Tnfrsf13cBcmd1/Tnfrsf13c+
MRL.Cg-Tnfrsf13cBcmd1 Faslpr 		decreased B cell number J:122315
decreased marginal zone B cell number J:122315
Fastm1Ach/Fastm1Ach
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae 		decreased ovarian tumor incidence J:161953
Fastm1Cgn/Fastm1Cgn
Mogtm1(cre)Gkl/Mog+
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
involves: 129S2/SvPas * C57BL/6 		decreased susceptibility to experimental autoimmune encephalomyelitis J:114741
normal immune system phenotype J:114741
Fastm1Cgn/Fastm1Cgn
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
involves: 129S2/SvPas * C57BL/6 		decreased susceptibility to experimental autoimmune encephalomyelitis J:114741
Fastm1Osa/Fastm1Osa
Gzmatm1Simn/Gzmatm1Simn
Gzmbtm1Ley/Gzmbtm1Ley
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		increased susceptibility to parasitic infection J:81397
Fastm1Vbo/Fastm1Vbo
Tg(Ins2-cre)25Mgn/0
Tg(Ins2-HA)165Bri/0
Tg(Tcra/Tcrb)1Vbo/0
Not Specified 		increased susceptibility to autoimmune diabetes J:85985
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory